Edition:
United States

Medtronic PLC (MDT.N)

MDT.N on New York Stock Exchange

82.50USD
9:49am EST
Change (% chg)

$-0.81 (-0.97%)
Prev Close
$83.31
Open
$83.00
Day's High
$83.37
Day's Low
$81.59
Volume
211,461
Avg. Vol
1,388,644
52-wk High
$89.71
52-wk Low
$76.52

Select another date:

Medtronic quarterly revenue beats, margins disappoint

Medical device maker Medtronic Plc's quarterly revenue beat analysts' expectations as new product launches drove sales across its business units, but weaker-than-expected margins clouded the earnings report.

UPDATE 2-Medtronic quarterly revenue beats, margins disappoint

Feb 20 Medical device maker Medtronic Plc's quarterly revenue beat analysts' expectations as new product launches drove sales across its business units, but weaker-than-expected margins clouded the earnings report.

BRIEF-Medtronic Q3 GAAP Loss Per Share $1.03

* ‍RTG WORLDWIDE Q3 REVENUE OF $1.944 BILLION INCREASED 7 PERCENT, OR 5 PERCENT ON A CONSTANT CURRENCY BASIS​

Medtronic posts loss due to $2.2 bln U.S. tax law charge

Feb 20 Medtronic Plc reported a third-quarter loss on Tuesday, compared with a year-ago profit, hurt by a $2.2 billion charge related to recent changes in U.S. tax laws.

Cardinal Health profit beats on CVS tie-up, Medtronic unit buy

Cardinal Health's quarterly profit topped analysts' estimates as the U.S. drug distributor benefited from its purchase of Medtronic Plc's patient care business and a tie-up with drugstore chain CVS Health Corp .

UPDATE 3-Cardinal Health profit beats on CVS tie-up, Medtronic unit buy

* Shares up nearly 5 pct (Adds comments from conference call, analyst comments, background, share movement)

BRIEF-Medtronic And Philips Partner To Innovate In Lung Cancer Management

* MEDTRONIC AND PHILIPS PARTNER TO INNOVATE IN LUNG CANCER MANAGEMENT

BRIEF-Medtronic Launches Enchant Study To Evaluate Chevar Parallel Graft Technique With The Endurant II/IIs Stent Graft System

* MEDTRONIC LAUNCHES ENCHANT STUDY TO EVALUATE CHEVAR PARALLEL GRAFT TECHNIQUE WITH THE ENDURANT II/IIS STENT GRAFT SYSTEM Source text for Eikon: Further company coverage:

BRIEF-Medtronic Receives FDA Clearance For Riptide Aspiration System

* MEDTRONIC RECEIVES FDA CLEARANCE FOR RIPTIDE(TM) ASPIRATION SYSTEM

BRIEF-FDA Approves Innovative Clinician Programmer For The Medtronic Synchromed II Intrathecal Drug Delivery System

* FDA APPROVES INNOVATIVE CLINICIAN PROGRAMMER FOR THE MEDTRONIC SYNCHROMED II INTRATHECAL DRUG DELIVERY SYSTEM FOR CHRONIC PAIN AND SEVERE SPASTICITY Source text for Eikon: Further company coverage:

Select another date: